Press Releases Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Real-time Estimate Cboe BZX Other stock markets 08:59:47 17/05/2024 pm IST			5-day change	1st Jan Change
0.38 ^USD	+1.60%		+3.08%	-12.76%

07/05	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference	14/05	AQ
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results	07/05	AQ
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04	AQ
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	23/04	AQ
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting	23/04	AQ
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting	08/04	AQ
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results	25/03	AQ
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results	19/03	AQ
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference	11/03	AQ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	07/02	AQ
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference	16/01	AQ
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results	13/11	AQ
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results	07/11	AQ
Theriva™ Biologics to Participate in the BIO-Europe Conference	03/11	AQ
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	02/11	AQ
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23/23/23	AQ
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	16/23/16	AQ
Theriva Biologics to Participate in the Emerging Growth Conference	28/23/28	AQ
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results	08/23/08	AQ
Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	02/23/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Press Releases

Filters